Bekelman J.E., Mitra N., Handorf E.A., Uzzo R.G., Hahn S.A., Polsky D., Armstrong K.
Journal of Clinical Oncology 2015 33:7 (716-722)
Purpose: We examined whether the survival advantage of androgen-deprivation therapy with radiotherapy (ADT plus RT) relative to ADT alone for men with locally advanced prostate cancer reported in two randomized trials holds in real-world clinical practice and extended the evidence to patients poorly represented in the trials. Methods: We conducted nonrandomized effectiveness studies of ADT plus RT versus ADT in three groups of patients diagnosed between 1995 and 2007 and observed through 2009 in the SEER-Medicare data set: (1) the randomized clinical trial (RCT) cohort, which included men age 65 to 75 years and was most consistent with participants in the randomized trials; (2) the elderly cohort, which included men age > 75 years with locally advanced prostate cancer; and (3) the screen-detected cohort, which included men age ? 65 years with screen-detected high-risk prostate cancer. We evaluated cause-specific and all-cause mortality using…(vermás)